Included Research Compounds : TB-500 A synthetic peptide fragment derived from thymosin beta-4, researched for its actin-binding properties and involvement in cytoskeletal organization and cellular migration models
After lyophilization, the vials are fully sealed
Hallare J, Gerriets V
Furthermore, to refine the experimentally determined structural model and explore interaction dynamics, we conducted extensive MD simulations
1 Adverse reactions that occurred in 2% of patients treated with RADICAVA and 2% more frequently in placebo-treated patients 1 Hypersensitivity reactions and cases of anaphylaxis have been reported in postmarketing reports with RADICAVA 1 Discontinuations were not associated with contusion, gait disturbance, or headache in patients treated with RADICAVA 2 No known drug interactions based on in vitro drug interaction studies 1 RADICAVA ORS Was Generally Well Tolerated 1,3 The safety profile of RADICAVA ORS was demonstrated in a 6-month, phase 3, open-label clinical trial in 185 patients
however, the yield and productivity are usually quite low